Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Lymphoma Clinical Trial

Official title: Phase II Trial of Subcutaneous Injections of Interleukin-2 for the Treatment of Mycosis Fungoides or the Sezary Syndrome

Status Terminated

Clinical Trial Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells.

PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.

Clinical Trial Description

OBJECTIVES:

• Determine the response rate in patients with mycosis fungoides or Sezary syndrome treated with interleukin-2 (IL-2).

• Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive interleukin-2 subcutaneously for 4 consecutive days a week for 6 consecutive weeks. Treatment repeats every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or stable disease continue treatment for 2 courses past best response. Patients who demonstrate a persistent partial response continue treatment in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for survival.

PROJECTED ACCRUAL: A total of 15-35 patients will be accrued for this study. ;

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Mycoses
• Mycosis Fungoides
• Sezary Syndrome

• NCT number: NCT00005788
• Study type: Interventional
• Source: Northwestern University
• Status: Terminated
• Phase: Phase 2
• Start date: April 1997
• Completion date: January 2002